Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
SANTA CLARA, Calif., May 19, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces continued growth in 2017 with dramatic first quarter results.
In Q1 17 revenue reached NT$493 million, a 34% YOY (year-over-year) growth. Gross margin reached 49.3% with EPS (earnings per share) of NT$0.13. With the strong demand for Oncology and Immunology therapy, the company anticipates sustained revenue growth and increased profitability through 2017.
To achieve this growth CrownBio leveraged its existing platforms of patient-derived xenograft (PDX) and cell line derived xenograft pharmacology models, and expanded immuno-oncology translatable models while broadening the portfolio offering to inflammatory disease. This extensive portfolio supports the therapeutic continuum of Oncology, Cardiovascular, Metabolic, and Inflammatory disease research.
“The double and triple digit growth regionally, proves CrownBio’s global reach and strong local presence is servicing our client base with sound scientific offerings,” said Laurie Heilmann, SVP of Global Strategy, Business Development and Marketing, “Our Immuno-Oncology, Cardiovascular, and Metabolic translatable models, along with strong performance in Europe, US, and the Western APAC region were significant contributors to the growth.”
Continued diversity across their service offerings, while remaining client centric, has enabled CrownBio to secure confidence by demonstrating growth in 75% of the top tier pharma companies. “CrownBio brings clarity to drug discovery with end to end solutions that help recognize the next clinical candidate sooner,” said Dr. Jean-Pierre Wery, CEO. “We will further advance preclinical and clinical research through accelerating development of technologies, including biomarker discovery and precision diagnosis that are needed to bring the right molecule to market.”
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
